Growth vs. Value Part II Using Kailash Constructs to Amplify the Eventual Mean Reversion
Introduction: Part 1 Recap The Case for Kailash Value Picks The Case for Kailash Growth Picks The Compelling History of our Top Ranked Value vs. Bottom Ranked Growth Conclusion Exhibits Introduction: Part I Recap In Growth vs. Value Part ...
Growth vs. Value – A Predisposition towards the Importance of Price has been Painful
Introduction: The Historical Context of the Pain Trade for Value Oriented Investors Trouble Comes in Threes Could the Glamour in Growth Lose its Glow? Conclusion Exhibits Introduction: The Historical Context of the Pain Trade for Value Oriented Investors Kailash ...
Dividend Growers: Performance Since 2006
Fig.1: Since 2006 Kailash's Dividend Long Picks have Added 2-3% Battling Average Improvement...
Amazon: Notes from Agnostics The Lost Impact of Large Numbers
Introduction: Keeping it Simple A Bankable Year: How Much “Free” is in Free Cash Flow? The Lost Impact of Large Numbers: What does $26.666 Billion Mean? Conclusion: The Munificence ...
The Defense Dilemma Revisited – Proof From the Past and Picks For the Present
Introduction: Better a Seller Than a Buyer Be The Defense Dilemma Revisited Defensive Boost to Positive Earners Conclusion Exhibits Appendix: R1000 Introduction: Better a Seller Than a Buyer Be In Kailash’s recent paper, Better a Seller Than a Buyer ...
Better a Seller than a Buyer Be? – The Buffett Valuation Metric & the Notion of “Cheap at the Peak”
Introduction: Market Cap to GDP Appears Pricey The Numbers Required to Resolve Market Cap to GDP are Anything but Pretty How the Recent Rout Stacks Up vs. History Is ...
Private vs. Public Markets – Identifying Potential Sources of Risk and Reward
Introduction: The Pension Fund Propellant The Appeal of Private Equity’s Purported Promise The Complications of Competition The Concern with IPOs: A Seller’s Market Dry Powder Targets: Potential Winners Conclusion & Exhibits Introduction: The Pension Fund Propellant With 2018 IPO ...
Biotech Update: Revisiting our 2015 Report – A Similar but Slightly Less Compelling Conclusion
Introduction Biotech: M&A and IPO Data Update Valuation: A Biohazard in Biotech? Conclusion: Finding Opportunity in Biotech Appendix: Does Valuation Matter Within Biotech Introduction Over the last few months several partners of Kailash Capital Research, LLC ’s work have ...
Biotech Update, Part II – Finding Opportunity in Biotech
Introduction Largest Decile of Biotech vs. the Rest Conclusion Exhibits Introduction In part one of our two part Biotech update series titled “Biotech Update: Revisiting our 2015 Report”, Kailash updated our 2015 paper “Where Are We in the Biotech ...
Pain Is the Parent of all Progress: Small & Mid Cap
The Case for Contrarians: Why the Low Momentum Anomaly May Represent a Compelling Opportunity for Active Managers Introduction: Is a Preponderance of Underperformers a Problem? Momentum Seeking: We Wish We Were Traditional Quants (With Very Recent Hindsight)... Pounding the ...
A Market Cap Concentration Caution Flag Part II: Truth & Transparency Trump Narrative Convention
Introduction: The Nifty Five Revisited The Law of Large Numbers Capitalizing on the Kailash Rankings when The Nifty Five are Running Rich Fundamentals Today vs. Historical Periods of Nifty ...
A Market Cap Concentration Caution Flag? What has it meant historically and where we are today
Introduction: “Behemoths Have Dominated the Market Before, but Tech is Different,” WSJ, June 15, 2018 1 The 5 Largest Firms, “The Nifty-Five”, from Naïve to Nefarious? A Study of ...
